A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Sponsor: Shire
Listed as NCT04444895, this PHASE3 trial focuses on Angioedema and remains completed. Sponsored by Shire, it has been updated 10 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2023 — Jul 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2022 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
- Takeda Development Center Americas, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .